Disease · MONDO_0000481
Targets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 14 of 14
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | 7 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor; Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | 1 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | Phase 2 | https://conductscience.org/library/genes/774 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor agonist | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GRIA1 | Glutamate receptor ionotropic AMPA | 1 | Glutamate receptor ionotropic AMPA antagonist | Phase 1/2 | https://conductscience.org/library/genes/2890 | Drugs and targets |
| GRIA2 | Glutamate receptor ionotropic AMPA | 1 | Glutamate receptor ionotropic AMPA antagonist | Phase 1/2 | https://conductscience.org/library/genes/2891 | Drugs and targets |
| GRIA3 | Glutamate receptor ionotropic AMPA | 1 | Glutamate receptor ionotropic AMPA antagonist | Phase 1/2 | https://conductscience.org/library/genes/2892 | Drugs and targets |
| GRIA4 | Glutamate receptor ionotropic AMPA | 1 | Glutamate receptor ionotropic AMPA antagonist | Phase 1/2 | https://conductscience.org/library/genes/2893 | Drugs and targets |
| SLC18A2 | Synaptic vesicular amine transporter | 1 | Synaptic vesicular amine transporter inhibitor | Phase 2 | https://conductscience.org/library/genes/6571 | Drugs and targets |
| SV2A | Synaptic vesicle glycoprotein 2A | 1 | Synaptic vesicle glycoprotein 2A modulator | Phase 2 | https://conductscience.org/library/genes/9900 | Drugs and targets |
| VAMP2 | Vesicle-associated membrane protein 2 | 1 | Vesicle-associated membrane protein 2 inhibitor | Approval | https://conductscience.org/library/genes/6844 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000481/targets